{"classes":[{"categories":[{"measurements":[{"comment":"No participants had adequate PK profiles (below lower limit of quantification).","groupId":"OG000","spread":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Blood samples were collected to assess adequate PK profiles. Participants were not enrolled in Part 1a, 1b.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with KRAS G12C-mutant Advanced Solid Tumors were treated with a single dose of BMS-986466 10 mg orally (PO) on Cycle 1 Day 1 and Day 9 and followed by regular administration from Cycle 3 Day 1 till study discontinuation. Participants were also administered with adagrasib 400 mg twice a day (BID) starting on Cycle 1 Day 4.","id":"OG000","title":"Part 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) evaluable population is a subset of PK participants (all participants who received at least 1 dose of BMS-986466 and/or adagrasib and had any available concentration-time data) which consist of all participants in the PK population with adequate PK profiles. Prespecified to be collected for Part 1 only.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (Each cycle consist of 28 days)","title":"Part 1: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-T])","type":"SECONDARY","unitOfMeasure":"mcg*hr/mL"}